undamentalytics Newsletter

Dianthus Therapeutics, Inc. valuation and forecast

Explore the models for Dianthus Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Dianthus Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

18 analysts, Oct 2026
Buy18100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20261718
  2. Sep 20261617
  3. Aug 20261515
  4. Jul 20261515

Counts of recommendations published by analysts covering Dianthus Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

DNTH valuation questions

How does Fundamentalytics value Dianthus Therapeutics, Inc.?
We use the models that fit Dianthus Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Dianthus Therapeutics, Inc.

Compare with peers